Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

- PMLiVE

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Hepatitis C drug only recommended use for one out of three licenced indications

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

Roche - Basel

Roche moves eye drug lampalizumab into phase III

It could be the first treatment for geographic atrophy

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

Roche - Basel

Roche wins early use RA approval for RoActemra in Europe

Adds to existing indications in arthritis and Castleman’s disease

- PMLiVE

Levinson resigns from Roche board

Declares conflict of interest due to his position as CEO at Calico

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

- PMLiVE

Germany’s IQWiG denies Astellas’ incontinence drug

But Janssen receives recommendation for hepatitis C treatment Olysio

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

Diagnostics are rising up the pharma value chain

Pharma interview: Anssi Pulkkinen from Roche Diagnostics, Finland on the increasing prominence of diagnostics

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

Chugai soars on Roche buyout rumours

Reports circulating that Swiss company is poised to make $10bn offer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links